Bloggers

Lisa Banket
Cofounding Partner/Publisher
VIEW MY COMPLETE PROFILE
Taren Grom
Cofounding Partner/Editor-in-Chief
VIEW MY COMPLETE PROFILE
Heather Hummel
Project Coordinator
VIEW MY COMPLETE PROFILE
Dan Limbach
Producer, Webcast Network
VIEW MY COMPLETE PROFILE
Denise Myshko
Managing Editor
VIEW MY COMPLETE PROFILE
Kim Ribbink
Features Editor
VIEW MY COMPLETE PROFILE
Robin Robinson
Senior Editor
VIEW MY COMPLETE PROFILE
Marah Walsh
Cofounding Partner/New Business Development
VIEW MY COMPLETE PROFILE

PharmaVOICE Editors' Blog

Thursday, September 5, 2013

Risk-Based Monitoring for Late-Phase Research

PRA
Risk-based Monitoring White Paper
A number of factors are leading to the paradigm shift in the way that clinical research is conducted. The increasing cost of research and the adoption of EDC technologies that provide real-time access to data have forced the industry to look at optimized methods of conducting clinical studies. In addition, several studies have shown that 100% SDV may not result in higher data quality. All of these factors have led to increased interest in RBM strategies.

Download white paper
Risk-Based Monitoring for Late-Phase Research

Download Related Podcast
Risk-Based Monitoring for Late Phase: Implementation Strategies

Download Podcast Transcript

See All PharmaVOICE White Papers

See All PharmaVOICE Podcasts

Risk Based Monitoring

0 comments:

Post a Comment